Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis A Eichenauer

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Expert Review of Hematology|July 1, 2017
The evolving role of targeted drugs in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Leukemia & Lymphoma|November 4, 2009
Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Blood|July 29, 2017
R-CHOP in NLPHL: who should receive it?Dennis A Eichenauer, Andreas Engert
Blood|September 3, 2020
How I treat nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pathology|December 2, 2019
Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphomaSylvia Hartmann, Dennis A Eichenauer
Current Opinion in Oncology|July 5, 2021
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
International Journal of Hematology|October 12, 2012
Advances in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|January 4, 2023
[Hemolytic anemia in emergency and intensive care medicine]Dennis A Eichenauer, Matthias Kochanek
Hematological Oncology|June 19, 2013
VII. Management of nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
European Journal of Haematology|April 23, 2014
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Expert Review of Hematology|July 1, 2017
The evolving role of targeted drugs in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Leukemia & Lymphoma|November 4, 2009
Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Blood|July 29, 2017
R-CHOP in NLPHL: who should receive it?Dennis A Eichenauer, Andreas Engert
Blood|September 3, 2020
How I treat nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pathology|December 2, 2019
Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphomaSylvia Hartmann, Dennis A Eichenauer
Current Opinion in Oncology|July 5, 2021
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
International Journal of Hematology|October 12, 2012
Advances in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|January 4, 2023
[Hemolytic anemia in emergency and intensive care medicine]Dennis A Eichenauer, Matthias Kochanek
Hematological Oncology|June 19, 2013
VII. Management of nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
European Journal of Haematology|April 23, 2014
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pageof 13